Joseph Burchenal, MD
Interventional Cardiology · Littleton, CONPI 1114946662
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,263 of the $4,419 with a category attached, or 73.8%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $1,632 and has fallen 50.7% since, to $805 in 2025. That places this record below the midpoint for interventional cardiology clinicians in CO, where the typical reported total is $6,820.
Across 116 payments — averaging $38.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$942
- Boston Scientific$677
- Abiomed$524
- E.r. Squibb & Sons, L.L.C.$342
- Pfizer$342
- AstraZeneca$232
- plus $1K from 23 others
Across 77 payments — averaging $8139.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$568K
- Esperion Therapeutics, Inc.$29K
- Janssen Research & Development, LLC$28K
- CSL Behring$2K
What the payments were for
- Travel & lodging$1,15626%
- Food & beverage$3,26374%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 9 | $942 |
| Boston Scientific | 9 | $677 |
| Abiomed | 1 | $524 |
| E.r. Squibb & Sons, L.L.C. | 20 | $342 |
| Pfizer | 18 | $342 |
| AstraZeneca | 8 | $232 |
| Impulse Dynamics (USA) Inc. | 1 | $172 |
| Cvrx, Inc. | 1 | $165 |
| Heartflow, Inc. | 1 | $134 |
| Amgen | 8 | $134 |
| Alnylam Pharmaceuticals Inc. | 4 | $106 |
| Bridgebio Pharma, Inc. | 5 | $105 |
| Novartis | 5 | $99 |
| Bayer | 3 | $51 |
| Atricure, Inc. | 2 | $49 |
| Novo Nordisk | 1 | $34 |
| Scpharmaceuticals Inc. | 2 | $34 |
| Akcea Therapeutics, Inc. | 2 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Johnson & Johnson | 2 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Gilead | 1 | $25 |
| Abbott | 1 | $23 |
| AbbVie | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Merck | 2 | $16 |
| Shockwave Medical, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$524
- GENERAL - THERAPIES$344
- OPTIMIZER$344
- Barostim Neo System$165
- BRILINTA$123
- CROSSBOSS$110
How this compares
$4,419 in reported general payments places this provider in the 35th percentile of 111 interventional cardiology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 306 | $434,739 |
| Repatha SureclickEvolocumab | 102 | $115,745 |
| JardianceEmpagliflozin | 72 | $104,323 |
| XareltoRivaroxaban | 55 | $78,662 |
| EntrestoSacubitril/Valsartan | 46 | $51,992 |
| Praluent PenAlirocumab | 35 | $34,027 |
| VascepaIcosapent Ethyl | 35 | $33,291 |
| BrilintaTicagrelor | 12 | $14,923 |
| Repatha SyringeEvolocumab | 16 | $9,666 |
| Prasugrel Hcl | 80 | $6,810 |
| Metoprolol Succinate | 421 | $5,823 |
| Rosuvastatin Calcium | 379 | $4,944 |
| Atorvastatin Calcium | 534 | $4,837 |
| Ezetimibe | 186 | $3,431 |
| ClopidogrelClopidogrel Bisulfate | 276 | $2,743 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $342 | $434,739306 claims |
| Boehringer IngelheimJardiance | $19 | $104,32372 claims |
| Johnson & JohnsonXarelto | $28 | $78,66255 claims |
| NovartisEntresto | $99 | $51,99246 claims |
| AstraZenecaBrilinta | $232 | $14,92312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 111 interventional cardiology providers in Colorado.
Other interventional cardiology in Littleton
- Cinthia BatemanLittleton$101K
- Lee MacdonaldLittleton$57K
- Sean EnkiriLittleton$18K
- Ira DauberLittleton$8K
- Ehrin ArmstrongEnglewood$718K
- Gareth MorganAurora$536K
- Jamaluddin MolooAurora$272K
- Jenny Zablah AlabiAurora$269K
- Srinivas IyengarBoulder$254K
- Nima AghiliLakewood$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.